Following U.S. Stocks are among the “Most Active” Stocks in the course of recent trading session, Monday: Apple Inc (NASDAQ:AAPL), Pfizer Inc (NYSE:PFE), Bank of America Corp (NYSE:BAC), MEI Pharma Inc (NASDAQ:MEIP)
- Pfizer Inc (NYSE:PFE), with shares picked up 2.57% is now trading at $35.11, hitting new 52-week high of $35.26. The Stock is active as 21.07M shares changed hands versus its average volume of 29.83M shares.
- Bank of America Corp (NYSE:BAC), with shares declined -0.47% is now trading at $15.77. The Stock is active as 19.13M shares changed hands versus its average volume of 95.39M shares.
- Apple Inc (NASDAQ:AAPL) with shares enhanced 0.91% is now trading at $127.98. The Stock is active as 14.61M shares changed hands versus its average volume of 58.32M shares.
- MEI Pharma Inc (NASDAQ:MEIP) with shares dwindled -68.25% is now trading at $2.01, hitting new 52-week low of $1.87. The Stock is active as 12.79M shares changed hands versus its average volume of 1.01M shares.
Latest NEWS regarding these Stocks are depicted underneath:
Pfizer Inc. (NYSE:PFE)
Today, Pfizer Inc. (PFE), and Eli Lilly and Corporation (LLY) declared recently that they are preparing to resume the Phase 3 clinical program for tanezumab. As a result, Pfizer anticipates to receive a $200 million upfront payment from Lilly in accordance with their partnership contract. This declaration follows a decision by the U.S. Food and Drug Administration (FDA) to lift the partial clinical hold on the tanezumab development program after a review of a robust body of nonclinical data characterizing the sympathetic nervous system response to tanezumab. The data were presented to the FDA in February 2015.
In the preceding clinical studies of more than 11,000 patients, tanezumab demonstrated clinically meaningful efficacy vs. placebo and other select ordinarily used pain medicines. A partial clinical hold has been in place for tanezumab and all other anti-nerve growth factor antibodies since December 2012 due to adverse changes in the sympathetic nervous system of mature animals. Studies in terminal cancer pain were allowed to proceed.
It is estimated that nearly one in five adults suffer from chronic pain.
Tanezumab is a humanized monoclonal antibody that selectively targets nerve growth factor (NGF), a regulator of pain processing and sensitivity. NGF levels raise as a result of injury or inflammation and in chronic pain states. Tanezumab selectively binds to NGF, thereby inhibiting this protein from activating pain-signaling neurons.
Lilly is a global healthcare leader that unites caring with discovery to make life better for people around the world.
Pfizer Inc., a biopharmaceutical corporation, discovers, develops, manufactures, and sells healthcare products worldwide. The corporation operates through Global Innovative Pharmaceutical (GIP); Global Vaccines, Oncology and Consumer Healthcare (VOC).
Bank of America Corporation (NYSE:BAC)
Today, Bank of America Corporation (BAC), declared a $1 million grant to Water.org, a global organization that provides innovative, community-led and market-based solutions that change lives through safe water and sanitation. The grant will empower 100,000 people in southern India to obtain safe water and sanitation solutions, accelerating positive change in their homes and communities. This will be achieved through a Water.org program, WaterCredit, which enables people in need to access small loans for water connections and toilets.
According to Water.org, water-related illness worldwide, such as diarrhea, is among the leading causes of death in children under five years old, listed with deadly diseases such as malaria. Moreover, according to the World Health Organization, every dollar invested in water and sanitation generates about a $4 economic return. The World Economic Forum, in its recently released 2015 Global Risk Assessment, ranked water crises as the number one global risk in terms of influence on people’s health and quality of life.
Collecting scarce water in impoverished communities is usually the job of women and girls, often taking hours each day. Similar initiatives have shown that with the availability of clean, safe water, their lives can be transformed: Women have significantly more time to pursue paid work, and girls have more time to attend school. Women constitute 91 percent of WaterCredit borrowers globally.
Water.org said that the grant from the Bank of America Charitable Foundation will benefit three of its local WaterCredit partners in the region, assisting them to provide small loans for families to pay for water access and sanitation. As the loans are repaid, they will become a new, sustainable source of affordable water and sanitation financing in the region.
Through its $70 billion business aim to advance lower-carbon economic solutions through lending, equipment finance, capital markets and advisory activities, carbon finance and investment advice and solutions for clients globally, Bank of America remains committed to environmental sustainability.
Bank of America Corporation, through its auxiliaries, provides banking and financial products and services for individual consumers, small and middle market businesses, institutional investors, large corporations, and governments worldwide.
Apple Inc. (NASDAQ:AAPL)
Cantor Fitzgerald analyst Brian White has a big call for Apple Inc. (AAPL) market cap: $1 trillion.
In a note to clients on Monday, White raised his price target on Apple shares to $180 from $160. At $180, Apple’s market cap would be more than $1 trillion. White maintains a “Buy” rating on shares of the iPhone maker.
White says his current model assumes Apple Watch sales of 20.6 million in the first year on the market and sales of 25.1 million in Apple’s fiscal-year 2016.
Potential for a car from Apple also excited White, who estimates a $549 billion opportunity in the US market.
Apple Inc. designs, manufactures, and markets mobile communication and media devices, personal computers, and portable digital music players worldwide.
MEI Pharma, Inc. (NASDAQ:MEIP)
Today, MEI Pharma, Inc. (MEIP), an oncology corporation focused on the clinical development of novel therapies for cancer, declared top-line data from a randomized Phase II clinical study of its investigational drug candidate Pracinostat in combination with azacitidine in patients with formerly untreated intermediate-2 or high-risk myelodysplastic syndrome (MDS). The double-blind, placebo-controlled study enrolled a total of 102 patients, randomized one-to-one, at 19 sites in the U.S.
According to the top-line data, the combination of Pracinostat and azacitidine showed no difference in the rate of complete remission (CR), the study’s primary endpoint, contrast to azacitidine alone. Data from event-driven endpoints, counting duration of response, event and progression free survival and overall survival, are immature and will require longer follow-up in order to achieve meaningful conclusions. There were no new or unpredictable toxicities observed in the study. Fatigue, gastrointestinal toxicities and myelosuppresion occurred more frequently in the combination group and resulted in a higher rate of drug discontinuations contrast to azacitidine alone. The Corporation anticipates to present full results of the study at a scientific meeting later this year.
At the American Society of Hematology (ASH) Annual Meeting In December 2014, the corporation stated noteworthy clinical activity from 33 evaluable patients in an open-label, single-arm Phase II study of Pracinostat and azacitidine in elderly patients with newly diagnosed acute myeloid leukemia (AML). Further follow-up indicates that the response rate and overall survival of these patients continued to raise. To date, 12 patients have been on study for more than six months, counting five who have surpassed one year. Data from all 50 patients enrolled in this study have been presented for presentation at the European Hematology Association (EHA) Annual Congress in June 2015.
MEI Pharma, Inc. (MEIP) is a San Diego-based oncology corporation focused on the clinical development of novel therapies for cancer. The Corporation’s portfolio of drug candidates comprises Pracinostat, a potential best-in-class, oral HDAC inhibitor presently being developed for advanced hematologic diseases, such as MDS and AML. MEI Pharma is also developing ME-344, a mitochondrial inhibitor presently in a Phase Ib study in combination with topotecan in patients with small cell lung or ovarian cancer who failed initial therapy.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
